As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.
24 Analysts have issued a Janux Therapeutics Inc forecast:
24 Analysts have issued a Janux Therapeutics Inc forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 10 10 |
23%
23%
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -142 -142 |
70%
70%
|
|
| EBIT (Operating Income) EBIT | -144 -144 |
68%
68%
|
|
| Net Profit | -102 -102 |
68%
68%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Janux Therapeutics, Inc. operates preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded in June 2017 and is headquartered in La Jolla, CA.
| Head office | United States |
| CEO | David Campbell |
| Employees | 103 |
| Founded | 2017 |
| Website | www.januxrx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


